Filing Analysis
OptimizeRx Corporation (OPRX) has expanded its Board of Directors from six to seven members and appointed Mary Varghese Presti as an independent director, effective April 3, 2026. Ms. Presti will also serve on the Audit Committee as part of the company's ongoing board refreshment strategy.
Key Facts
- Appointment of Mary Varghese Presti to the Board of Directors effective April 3, 2026.
- Board size increased from six to seven members to accommodate the appointment.
- Ms. Presti was appointed to the Audit Committee.
- Compensation includes an annual cash retainer of $45,000 and an annual equity grant valued at approximately $175,000.
- An additional $10,000 annual cash retainer is provided for Audit Committee service.
- The appointment is described as part of an 'ongoing process to refresh and expand' the Board.
OptimizeRx Corp dismissed its independent auditor, UHY LLP, and appointed Grant Thornton LLP as its new accounting firm. While no accounting disagreements were reported, the company disclosed a persistent material weakness in internal controls over financial reporting related to third-party data accuracy.
Red Flags
- Persistent material weakness in internal control over financial reporting (ICFR) identified in both 2024 and 2025 filings.
- Auditor change occurring while a material weakness remains unresolved.
Key Facts
- Dismissed UHY LLP as the independent registered public accounting firm effective March 25, 2026.
- Appointed Grant Thornton LLP as the new auditor effective March 26, 2026.
- Audit reports for fiscal years ended December 31, 2025 and 2024 were unqualified.
- Disclosed a material weakness in internal control over financial reporting regarding the completeness and accuracy of data from third-party service organizations.
- The material weakness did not result in any restatements of financial statements.
OptimizeRx Corporation amended its financing agreement to extend its maturity date to 2029 and authorized a new $10 million share repurchase program. The company also reported its fourth quarter and full year 2025 financial results and provided 2026 guidance.
Key Facts
- Entered into Amendment No. 4 to the Financing Agreement on March 2, 2026.
- Financing maturity date extended by two years to October 11, 2029.
- Board authorized a $10 million share repurchase program effective March 12, 2026, through March 15, 2027.
- The 1% applicable premium under the financing agreement was extended through October 11, 2027.
- Repurchases will be funded using available cash and cash equivalents.